Clinical trials: D Vitamin Deficiency Patients
Calcium and Vitamin D Deficiencies
Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.
The purpose of this study is to compare the preference of Calcichew D3 500/400 (containing 500 mg calcium and 400 IU of vitamin D) with Adcal-D3 600/400 (containing 600 mg of calcium and 400 IU of vitamin D) in Test Group 1, and…
- Trial name
- NCT02457247
- Testing
- Calcichew D3, Adcal-D3, Kalcipos-D
- Where
- 9 sites in Germany, United Kingdom
- Volunteers
- 276 people
- Sponsor
- Takeda
Secondary Hyperparathyroidism
Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder
The purpose of this study is to evaluate the effect of thrice weekly intravenous (IV) administration of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney…
- Trial name
- NCT01414114
- Testing
- Etelcalcetide
- Volunteers
- 37 people
- Sponsor
- KAI Pharmaceuticals
Hemodialysis Patients, Vitamin D Insufficiency
Effect of Omega-3 Fatty Acid on Vitamin D Activation
Extra-renal sources of 1, 25-dihydroxyvitamin D can be increased to normal serum 1, 25-dihydroxyvitamin D levels in chronic kidney disease patients after administration of high dose 25-hydroxyvitamin D.
- Conditions
- Hemodialysis Patients, Vitamin D Insufficiency, Vitamin D Deficiency
- Trial name
- NCT01596842
- Testing
- Omega-3 fatty acid ethylester 90, Olive oil, cholecalciferol
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Dong-A University
Hypophosphatasia, Bone Disease
Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09
The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP who served as historical controls in ENB-006-09.
- Trial name
- NCT02235493
- Testing
- Retrospective Case Only
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypophosphatasia
Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan
This is a multicenter study in Japan. Eleven sites which have already participated in the investigator-initiated clinical study (Early Access Program) will participate in this study.The objective of this study is to gain further…
- Trial name
- NCT02531867
- Testing
- Asfotase Alfa
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hip Fracture, Vitamin D Deficiency
Vitamin D Levels in Frail Elderly Patients With a Hip Fracture
The purpose of this study is to assess whether all frail elderly admitted with hip fracture has a vitamin D deficiency, and if s-25(OH)D deficiency increases the risk of hip fracture in frail elderly.
- Trial name
- NCT01816711
- Where
- Denmark
- Volunteers
- 447 people
- Sponsor
- University of Aarhus
Chronic Renal Insufficiency, Proteinuria
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
A randomized clinical trial to determine if vitamin D repletion in CKD (Chronic Kidney Disease) patients with low vitamin D levels will decrease proteinuria, a marker of kidney damage.
- Trial name
- NCT01029002
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Albert Einstein College of Medicine
Rheumatoid Arthritis, Vitamin D Deficiency
Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis
The purpose of this study is to investigate the effect of vitamin D repletion on disease activity and disability in patients with rheumatoid arthritis.
- Trial name
- NCT01426347
- Testing
- Ergocalciferol
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- Johns Hopkins University
Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Safety, Efficacy, PK and PD of CTAP101 (calcifediol) ER Capsules for SHPT in HD Patients VDI
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Chronic Kidney Diseases, Vitamin D Deficiency, Stage 5 Chronic Kidney Disease
- Trial name
- NCT03602261
- Testing
- Calcifediol Oral Capsule
- Where
- 18 sites in United States
- Volunteers
- 44 people
- Sponsor
- OPKO Health, Inc.
Asthma, Bronchial
Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD)
Introduction: There are many cross-sectional studies in children and adults indicating that low vitamin D levels in asthmatic patients are correlated with poorer asthma control, poorer lung function, decreased response to…
- Trial name
- ACViD (NCT02805907)
- Testing
- Calcifediol
- Where
- Spain
- Volunteers
- 112 people
- Sponsor
- MurciaSalud
Hypophosphatasia (HPP)
Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)
The purpose of this study is to characterize the natural history of HPP in patients with Juvenile-onset HPP.
- Trial name
- NCT02104219
- Where
- 19 sites in United States, Australia and 6 more
- Volunteers
- 32 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Coronary Artery Disease, Chronic Kidney Disease
Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
The purpose of this study is to determine if vitamin D supplementation changes the results of certain tests associated with inflammation in the body using an oral, synthetic form of vitamin D called paricalcitol.
- Conditions
- Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
- Trial name
- VINCA-CKD (NCT01012414)
- Testing
- paricalcitol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Vitamin D Deficiency
Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis
Children with Cystic Fibrosis, ages greater than and equal to 36 months of age and less than or equal to 18 years of age, with a 25OHD level less than 30 ng/dL will be asked to participate in this study.
- Trial name
- NCT02613884
- Testing
- Treatment
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins All Children's Hospital
Vitamin D Deficiency, Hypertension
Vitamin D Deficiency in Patients With Hypertension
This study will evaluate the effects of Vitamin D replacement and the effects of an approved medication for hypertension, aliskiren (Tekturna), in patients with high blood pressure who have low levels of vitamin D in their blood.
- Trial name
- NCT00974922
- Testing
- Aliskiren, Cholecalciferol
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- UConn Health
Arterial Dysfunction, Chronic Kidney Disease
Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
The purpose of this study is to determine whether nutritional (cholecalciferol) or active vitamin D (calcitriol) supplementation improves vascular endothelial function in patients with stage IIIB and IV chronic kidney disease…
- Trial name
- NCT01384539
- Testing
- Cholecalciferol, Calcitriol
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Colorado, Denver
Obesity, Vitamin D Deficiency
Efficacy of Vitamin D Supplementation in Bariatric Surgery Patients
As the use of bariatric surgery for treatment of extreme obesity adults continues to rise, clinicians must be aware of pre-existing nutritional deficiencies in overweight and obese patients.
- Trial name
- NCT01385098
- Testing
- Vitamin D3 and Calcium
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Vadim Sherman, MD
Secondary Hyperparathyroidism, Chronic Kidney Disease
Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis
Paricalcitol capsules (Zemplar®) received marketing authorization in Sweden in late 2007 for the prevention and treatment of secondary hyperparathyroidism in patients with Stage 3 \& 4 Chronic Kidney Disease (CKD).
- Trial name
- CAPITOL (NCT01265992)
- Where
- 10 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)